All In Biotech

Drug Trial Radar · NCT01952444

Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers

An Open-Label, Randomized, Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics of ETI-204 Alone and in the Presence of Ciprofloxacin in Adult Volunteers

Last checked: Nov 20, 2026Latest source record: Apr 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

40

Actual

Start

Oct 29, 2013

Primary completion

Apr 9, 2014

Study completion Apr 9, 2014

Sponsor

Lead sponsor
Elusys TherapeuticsAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 30, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Evaluate the safety, tolerability and pharmacokinetics (PK) of intravenous (IV) ETI-204 alone and in the presence of IV and oral ciprofloxacin

Conditions

  • Inhalational Anthrax

Interventions

  • ETI-204Biological

    A single IV infusion of 16 mg/kg ETI-204 over 90 minutes on Day 1

  • CiprofloxacinDrug

    A single IV Infusion of 400 mg Ciprofloxacin over 60 minutes immediately following the infusion of ETI-204 on Day 1, followed by oral Ciprofloxacin (750 mg every 12 hours) on Days 2-8, and a final oral dose on the morning of Day 9.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced Adverse EventsTime frame: Up to 71 days or 101 days (30 days after the final study visit) for subjects with ongoing adverse events at the final study visit, for each group.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quintiles

    Overland Park, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.